54 Participants Needed

Enhanced PTSD Communication Strategies for Post-Traumatic Stress Disorder

(AWARE Trial)

EA
Overseen ByElizabeth Alpert, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Boston University
Stay on Your Current MedsYou can continue your current medications while participating
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if adding a writing exercise called AWARE can enhance existing PTSD treatments. Researchers will test two common PTSD therapies—cognitive processing therapy (CPT) and prolonged exposure (PE)—with and without AWARE to assess whether it improves patient communication with therapists and treatment outcomes. The trial targets adults with PTSD who have maintained stable psychiatric medication for at least four weeks. Participants will receive either CPT or PE, with or without the AWARE writing task. The goal is to discover if this new approach enhances treatment outcomes. As an unphased trial, this study provides a unique opportunity to explore innovative methods for improving PTSD treatment outcomes.

Will I have to stop taking my current medications?

The trial requires that participants have been stable on their psychiatric medications for at least 4 weeks, so you will not need to stop taking your current medications if they are stable.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that expressive writing, like that used in the AWARE program, is generally safe and well-received by people with PTSD. One study found that while expressive writing did not change PTSD diagnoses or symptoms, patients managed it well. This suggests that adding AWARE, which includes writing tasks to enhance communication between patients and therapists, is unlikely to cause harm.

Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE) are both proven and effective treatments for PTSD. Experts widely recommend these treatments as the best available, and they have been safely used by many patients over the years.

Overall, existing evidence supports the safety of all parts of the trial's treatments. Participants can feel confident that these therapies are well-researched and generally well-tolerated.12345

Why are researchers excited about this trial?

Researchers are excited about these treatments for PTSD because they integrate traditional therapies with a fresh approach that could enhance their effectiveness. Unlike the standard cognitive processing therapy (CPT) and prolonged exposure (PE), which rely solely on therapeutic sessions, the AWARE intervention adds a unique writing component designed to boost patient response and engagement. This adjunctive writing element aims to deepen the therapeutic impact by encouraging patients to articulate and process their experiences more thoroughly. By potentially amplifying the effects of CPT and PE, AWARE could lead to more significant improvements in PTSD symptoms, offering a promising advancement in how we approach treatment for this condition.

What evidence suggests that this trial's treatments could be effective for PTSD?

Studies have shown that cognitive processing therapy (CPT) and prolonged exposure (PE) effectively treat PTSD and rank highly in clinical practice guidelines. In this trial, participants will be randomized into different arms to receive either CPT or PE. One arm will include the adjunctive writing intervention, AWARE, which aims to amplify response and engagement. Research suggests that additional methods like AWARE might enhance these therapies. Although AWARE is still being tested, similar writing activities have been safe and well-received by PTSD patients, aiming to increase patient involvement and improve results during therapy.13678

Who Is on the Research Team?

EA

Elizabeth Alpert, PhD

Principal Investigator

National Center for PTSD at VA Boston Healthcare System, BU School of Medicine, Psychiatry

Are You a Good Fit for This Trial?

This trial is for adults with PTSD who are stable on psychiatric medications for at least a month. It's not suitable for individuals with unstable bipolar disorder, psychosis, severe substance use needing immediate attention, active suicidal or homicidal thoughts, those already in trauma-focused treatment, or with cognitive impairments like advanced dementia.

Inclusion Criteria

I have been diagnosed with PTSD.
I have been on the same psychiatric medications for over a month.

Exclusion Criteria

My bipolar disorder is currently not stable.
I do not have severe memory or thinking problems that would stop me from participating in therapy.
Current psychosis
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Case Series Phase

CPT or PE with AWARE provided to four adults with PTSD to pilot test and refine AWARE

8-15 weeks
Weekly sessions

Randomized Controlled Trial (RCT) Phase

50 adults with PTSD randomized to receive either CPT/PE as usual or CPT/PE with AWARE

8-15 weeks
Weekly sessions

Follow-up

Participants are monitored for safety and effectiveness after treatment

3 months

What Are the Treatments Tested in This Trial?

Interventions

  • Adjunctive writing to amplify response and engagement (AWARE)
  • Cognitive processing therapy (CPT)
  • Prolonged exposure (PE)
Trial Overview The study tests if an adjunctive writing intervention called AWARE can improve outcomes of two existing PTSD treatments: Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE). Participants will either receive standard CPT/PE or the same therapies supplemented with AWARE to enhance patient-therapist communication.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: CPT/PE with AWAREExperimental Treatment3 Interventions
Group II: CPT/PE TAUActive Control2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Boston University

Lead Sponsor

Trials
494
Recruited
9,998,000+

National Institute of Mental Health (NIMH)

Collaborator

Trials
3,007
Recruited
2,852,000+

Published Research Related to This Trial

Written Exposure Therapy (WET) is being tested in a randomized clinical trial with 150 active duty military service members to see if it is as effective as Cognitive Processing Therapy (CPT) for treating PTSD.
WET is a brief 5-session treatment that has shown low dropout rates and efficacy in previous studies, making it a promising alternative for military personnel who often face barriers to traditional PTSD treatments.
Study design comparing written exposure therapy to cognitive processing therapy for PTSD among military service members: A noninferiority trial.Sloan, DM., Marx, BP., Resick, PA., et al.[2020]
In a study of 46 participants with posttraumatic stress (PTS), a single imaginal exposure-writing assignment did not show significant efficacy in reducing PTS or comorbid depressive symptoms compared to other writing and control conditions.
Despite the lack of effectiveness for the imaginal exposure-writing task, both PTS and depressive symptoms decreased over time for all participants, suggesting that other factors may contribute to symptom improvement.
The efficacy of a single imaginal exposure-writing assignment in reducing posttraumatic stress and depressive symptoms: A pilot study.Vinke, YD., Truijens, F., van Polanen Petel, E., et al.[2020]
A study analyzing therapeutic texts from 51 PTSD patients revealed that writing about trauma exposure led to a significant increase in the use of negative emotional words like fear and depression compared to writing about biographical experiences.
Cognitive restructuring texts showed the highest emotional intensity, containing both negative and positive affective words, indicating that this component of writing therapy may be particularly effective in addressing a range of emotions.
[Courses of affects in an internet-based writing therapy for elderly war trauma survivors. A content analytic approach].Böttche, M., Berth, H., Knaevelsrud, C., et al.[2021]

Citations

Enhancing PTSD Treatment Outcomes by Improving ...The investigators have developed an Adjunctive Writing intervention for Amplifying Response and Engagement (AWARE), which was designed using health ...
Enhancing PTSD Treatment Outcomes by Improving ...The investigators have developed an Adjunctive Writing intervention for Amplifying Response and Engagement (AWARE), which was designed using ...
Do adjuvant interventions improve treatment outcome in ...The current systematic review aims to assess whether adjuvant interventions improve outcome among adult PTSD patients receiving TF-PT.
The Effectiveness of Behavioral Interventions in Adults with ...This review examined the effectiveness of behavioral interventions for adults with post-traumatic stress disorder (PTSD) triggered by physical injury or ...
Expressive writing and post-traumatic stress disorderResults. Expressive writing was acceptable to patients with PTSD and appeared safe to utilize. No changes in PTSD diagnosis or symptoms were observed, but ...
Treatment of Posttraumatic Stress Disorder: A State-of-the- ...This narrative state-of-the-art review paper describes the progress in the understanding and treatment of Posttraumatic Stress Disorder (PTSD).
7.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/18230238/
Expressive writing and post-traumatic stress disorderResults: Expressive writing was acceptable to patients with PTSD and appeared safe to utilize. No changes in PTSD diagnosis or symptoms were observed, but ...
Prebiotics as an adjunct therapy for posttraumatic stress ...This study suggests that targeting the intestinal microbiome through prebiotic supplementation could represent a promising avenue for enhancing treatment ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security